157 related articles for article (PubMed ID: 38659521)
1. Analysis and Reporting of Adverse Drug Reactions of Cosmetics at a Tertiary Care Hospital.
Paikray E; Bisoyi D; Rout A; Mishra V
Cureus; 2024 Mar; 16(3):e56856. PubMed ID: 38659521
[TBL] [Abstract][Full Text] [Related]
2. Cosmetovigilance in a tertiary care hospital: A prospective observational study.
Jyrwa S; Sebastian J; Shastry V
J Cosmet Dermatol; 2021 Mar; 20(3):804-811. PubMed ID: 32808451
[TBL] [Abstract][Full Text] [Related]
3. Causality methods in cosmetovigilance: comparison of Colipa and PLM versus global introspection.
Zweers PG; Gilmour NJ; Hepburn PA; Gerritsen RF; van Puijenbroek EP
Regul Toxicol Pharmacol; 2012 Aug; 63(3):409-17. PubMed ID: 22609380
[TBL] [Abstract][Full Text] [Related]
4. A cosmetovigilance survey in Europe.
Sautebin L
Pharmacol Res; 2007 May; 55(5):455-60. PubMed ID: 17368906
[TBL] [Abstract][Full Text] [Related]
5. An observational study on adverse reactions of cosmetics: The need of practice the Cosmetovigilance system.
Lucca JM; Joseph R; Hussain Al Kubaish Z; Mohammad Al-Maskeen S; Ali Alokaili Z
Saudi Pharm J; 2020 Jun; 28(6):746-753. PubMed ID: 32550807
[TBL] [Abstract][Full Text] [Related]
6. Cosmetovigilance: definition, regulation and use "in practice".
Vigan M; Castelain F
Eur J Dermatol; 2014; 24(6):643-9. PubMed ID: 25672787
[TBL] [Abstract][Full Text] [Related]
7. Notification of undesirable effects of cosmetics and toiletries.
Sportiello L; Cammarota S; de Portu S; Sautebin L
Pharmacol Res; 2009 Feb; 59(2):101-6. PubMed ID: 19028583
[TBL] [Abstract][Full Text] [Related]
8. Safety in Cosmetics and Cosmetovigilance, Current Regulations in Türkiye.
Altıokka İ; Üner M
Turk J Pharm Sci; 2022 Oct; 19(5):610-617. PubMed ID: 36317955
[TBL] [Abstract][Full Text] [Related]
9. Cosmetovigilance: A review of the current literature.
Toklu HZ; Antigua A; Lewis V; Reynolds M; Jones J
J Family Med Prim Care; 2019 May; 8(5):1540-1545. PubMed ID: 31198710
[TBL] [Abstract][Full Text] [Related]
10. Questionnaire-Based Study of 392 Women in Abbottabad, Pakistan, to Evaluate the Types of Cosmetic Products Purchased Between December 2018 and March 2019 and Their Associated Adverse Events.
Nisar F; Ali A; Shahid H; Iqbal MM; Khan H; Khan Q; Iqbal A; Samreen S; Syed W; Al-Rawi MBA
Med Sci Monit Basic Res; 2024 Mar; 30():e943048. PubMed ID: 38549239
[TBL] [Abstract][Full Text] [Related]
11. Awareness level regarding adverse reactions caused by cosmetic products among female patients: A cross-sectional study.
Nayak M; Ligade VS; Prabhu SS
J Cosmet Dermatol; 2023 Sep; 22(9):2512-2519. PubMed ID: 36999455
[TBL] [Abstract][Full Text] [Related]
12. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
Tissier MH; Lepagnol F
Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
[TBL] [Abstract][Full Text] [Related]
13. Cosmetics Use-Related Adverse Events and Determinants Among Jigjiga Town Residents, Eastern Ethiopia.
Bilal AI; Tilahun Z; Osman ED; Mulugeta A; Shekabdulahi M; Berhe DF
Dermatol Ther (Heidelb); 2017 Mar; 7(1):143-153. PubMed ID: 27882506
[TBL] [Abstract][Full Text] [Related]
14. Understanding the adverse effects of cosmetics: a pilot project in cosmetovigilance.
Sautebin L
Drug Saf; 2008; 31(5):433-6. PubMed ID: 18422386
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of dermo-cosmetic products: a global cosmetovigilance system to optimise product development and consumer safety.
Ribet V; Albinet Claudin L; Brinio E; Berthier A; Millet V; Halbeher C; Sauvaire L; Laborderie M; Lafosse S; Olivan A; Giordano Labadie F; Ferret PJ
Eur J Dermatol; 2021 Aug; ():. PubMed ID: 34463281
[TBL] [Abstract][Full Text] [Related]
16. Cosmetovigilance survey: are cosmetics considered safe by consumers?
Di Giovanni C; Arcoraci V; Gambardella L; Sautebin L
Pharmacol Res; 2006 Jan; 53(1):16-21. PubMed ID: 16183300
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
18. A Cross-sectional Survey-based Study of Knowledge, Attitude, and Practice Towards Uses of Cosmetics and Cosmetovigilance in India.
Siddiqui A; Ali N; Pandey A; Ali MD; Haider N; Khan MZ; Iqbal Z; Mirza MA; Alharthi S; Ansari MS; Mustafa G; Ahmad S
J Pharm Bioallied Sci; 2024; 16(1):31-37. PubMed ID: 38694964
[TBL] [Abstract][Full Text] [Related]
19. Adverse Cosmetic Reactions in a Pediatric Population Reported to the Chongqing Drug Administration in China From 2017 to 2021.
Wang S; Lyu J; Jiang Y; Li J; Diao Q
Dermatitis; 2023 Dec; ():. PubMed ID: 38126876
[No Abstract] [Full Text] [Related]
20. The impact of COLIPA guidelines for assessment of skin compatibility on the development of cosmetic products.
Meloni M; Berardesca E
Am J Clin Dermatol; 2001; 2(2):65-8. PubMed ID: 11705305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
